The Blood Pressure Progression of Psychedelics - An In-Depth Overview of Mechanisms, Phases, Risks, and Comparisons

Psychedelics influence not only consciousness, emotion, and perception, but also the autonomic nervous system. This means that they almost always affect blood pressure and heart rate, albeit to widely varying degrees. Unlike classical stimulants, these effects are rarely the primary goal of their action, but rather a secondary consequence of serotonergic, noradrenergic, or glutamatergic modulation, combined with psychological activation.

In this article, I discuss the blood pressure trajectory of the most important substances used in therapeutic and research contexts: psilocybin, LSD, MDMA, and ketamine. Subsequently, I present these substances in a single overview, both pharmacologically and clinically, with attention to safety, risk profiles, and practical implications.

General physiology: why psychedelics affect blood pressure

Blood pressure is acutely regulated by an interplay of:

1. It sympathetic nervous system (increasing)

2. It parasympathetic nervous system (lowering)

3. Vascular tone (vasoconstriction vs. vasodilation)

4. Cardiac output

Psychedelics intervene in this indirectly via three main mechanisms:

1. Serotonergic activation
   Specifically via the 5-HT₂A receptor, leading to central excitation and mild sympathetic activation.

2. Catecholamine modulation
   Some substances increase noradrenaline and adrenaline immediately (strongly with MDMA, moderately with ketamine, slightly with LSD).

3. Psychological arousal
   Fear, awe, loss of control, or intense emotion autonomously amplify the blood pressure response.

The result is almost always a temporary increase in blood pressure, but it tempo, the height and the duration vary greatly by product.

Psilocybin: mild, predictable and self-limiting

Psilocybin causes a modest and temporary increase in blood pressure, especially during the rise and peak.

Typical course

1. Turnout (30–60 min): slight increase

2. Peak (1–2 hours): systolic +10–20 mmHg

3. Platform/finishing: normalization

4. After the session: often normal to slightly lowered

Features

1. No sharp peaks

2. Highly setting-dependent

3. Hardly any cumulative effect

4. Easily dampened with relaxation and breathing

Clinical significance
In healthy individuals, psilocybin is considered cardiovascular as low risk. With well-controlled hypertension, it is often still justifiable, provided it is carefully supervised.

LSD: longer-lasting, stably elevated

LSD gives a moderately elevated but prolonged blood pressure, commensurate with its long operating time.

Typical course

1. Slow turnout (1–2 hours)

2. Peak (2–4 hours): systolic +10 to 25 mmHg

3. Long plateau (4–10 hours): steadily elevated

4. Tapering (10–24 hours): gradual normalization

Features

1. Less anxiety-inducing than ketamine or MDMA

2. Sustained sympathetic tone

3. Strong influence of mental intensity

4. Rarely extreme values in healthy individuals

Clinical significance
The risk lies less in height, but more in duration. In people with limited cardiovascular reserve, that prolonged load can be relevant.

MDMA: pronounced sympathetic activation

MDMA clearly distinguishes itself from classic psychedelics by its stimulant-like effect.

Typical course

1. Quick turnout (30–45 min)

2. Peak (1–3 hours): systolic +20 to 40 mmHg

3. Plateau (3–6 hours): fluctuating elevated

4. Rebound phase: possible temporary hypotension

Features

1. High peaks

2. Vasoconstriction

3. Temperature rise

4. Highly dependent on dose, exercise, and environment

Clinical significance
MDMA has it highest cardiovascular risk profile of the agents discussed here. Even in young, healthy people, risky values can occur under unfavorable conditions.

Ketamine: fast, powerful, short-lived

Ketamine causes a abrupt and marked increase in blood pressure, but short-lived.

Typical course

1. Rise within minutes

2. Peak (10–40 min): systolic +15 to 40 mmHg

3. Rapid normalization (60–90 min)

4. Sometimes mild hypotensive rebound

Features

1. Steep curve

2. Highly predictable

3. Less dependent on emotional content

4. Easy to monitor medically

Clinical significance
Ketamine is cardiovascularly intense, but due to the short duration easily manageable in medical settings.

Overview and comparison

Psychology versus pharmacology

An important distinction is that between psilocybin and LSD psychological factors often be more decisive than pure pharmacology. Anxiety can double blood pressure compared to a relaxed session. With MDMA and ketamine, on the other hand, the increase is largely pharmacologically driven and less influenced by mindset.

Safety implications

Caution or medical screening is essential in the following cases:

1. Uncontrolled hypertension

2. Recent heart rhythm disorders

3. Heart failure or coronary disease

4. Combination with blood pressure-raising medication

In guided sessions, therefore, the following are often agreed upon in advance:

1. Resting blood pressure measured

2. Stress factors minimized

3. Dosage strategies adjusted

Conclusion

All psychedelics temporarily raise blood pressure, but not in the same way.
Psilocybin and LSD are relatively mild and predictable on the cardiovascular side. Ketamine is powerful but short-lived. MDMA is the clear exception, with a pronounced sympathetic burden.

The clinical risk is determined by height × duration × individual vulnerability. Precisely for this reason, context, screening, and guidance are essential for therapeutic use. For the time being, psilocybin, particularly the lower dosages, appears to be most suitable for people with hypertension. Account should also be taken of possible lower blood pressure during the final stages of psilocybin's action, although this effect is mild.